BUZZ - Levi Strauss shares drop due to weak sales in the US and Europe

路透社2026/10/08 08:16

Show original

On October 8, Levi Strauss (LEVI.N) shares fell 1.3% in pre-market trading to $19.25 after the company reported lower-than-expected sales in the U.S. and Europe. BTIG commented: “This quarter, the European direct-to-consumer (DTC) business was hit by unusually warm weather, but as temperatures return to normal, foot traffic and sales trends have improved, maintaining a positive outlook in early Q4.” The brokerage also noted that the company remains strong in wholesale, e-commerce, and market share in jeans, but its “back-to-school” marketing campaign did not meet expectations. Benefiting from tariff refunds on Wednesday, the company raised its annual profit forecast and is betting on strong demand for its premium jeans and sweaters during the holiday season. Sixteen analysts have an average “buy” rating; the median price target is $27, according to LSEG. The stock has risen 6% year-to-date as of the previous close.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

October 8 - ** Shares of jeans maker Levi Strauss (LEVI.N) fell 1.3% in premarket trading to $19.25

** The company reported (link) lower-than-expected sales in the United States and Europe

** BTIG said: "This quarter, Levi’s direct-to-consumer (DTC) business in Europe was hit by unusually warm weather, but as temperatures normalized, foot traffic and sales trends improved and maintained a positive momentum in early Q4"

** The broker also noted that the company continues to show strong performance in wholesale, e-commerce, and jeans market share metrics, but its 'back-to-school' marketing campaign fell short of expectations

** On Wednesday, the company benefited from tariff rebates, raised its annual profit forecast, and is betting on strong demand for its premium jeans and sweaters during the holiday season

** The average rating from 16 analysts is "buy"; the median target price is $27 — data compiled by LSEG

** As of the close of the previous trading day, the stock is up 6% for the year

(To facilitate non-English speakers, Reuters automatically translates its reports into several other languages. As automated translations may contain errors or lack context, Reuters does not guarantee the accuracy of the automated translated text and provides it solely for readers' convenience. Reuters assumes no responsibility for any damage or loss resulting from the use of automated translation tools.)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)

路透社•2026/10/08 18:26